No surgery, seamless fit with existing abutments for unprecedented freedom of choice in bone anchored hearing solutions.
SOMERSET, NJ February 8 -- Oticon Medical announced today that it has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Ponto Abutment Extension. The new abutment extension seamlessly connects to existing abutments so users can upgrade their bone anchored hearing solutions without changing abutments or undergoing further surgery. The abutment extension provides freedom of choice to all BAHS users. The Ponto Abutment Extension completes the Ponto abutment family, making it the most flexible and versatile implant solution available.
“Freedom to choose is central to Oticon Medical’s People First philosophy,” says Oticon Medical President Jes Olsen. “We believe that hearing care professionals and users should have the freedom to choose whichever solution best suits their needs regardless of the brand. The unprecedented interface compatibility made possible with the new Ponto Abutment Extension means that even more people will be able to access the best sound technology available.”
Oticon Medical provides the most extensive family of abutments for variation in skin thicknesses. The Ponto abutment concept offers important features designed to improve some of the most critical aspects of the skin penetration for bone anchored hearing. Oticon Medical’s proprietary OptiFit™ and OptiGrip™ implant design concepts have been cleared by the FDA for use in tissue-preserving surgery. Like all Ponto abutments, the new Ponto Abutment Extension has a medical grade titanium surface.
For more information on the Oticon Medical Ponto System, the new Ponto Abutment Extension and the entire family of Ponto abutments, visit www.oticonmedical.com/us or the Oticon Medical Expo Page on AudiologyOnline.
